- Cassava Sciences stock realised a >4,000% gain between 2020 - 2021.
- The Alzheimer's therapy developer's shares collapsed after scientists and physicians (and short sellers of its stock) began to question Cassava's scientific rigour.
- There are catalysts in play that can move the share price 100s of percent upwards, or nearly 100% downward.
- These include the 2 Phase 3 trials now underway, more Open Label Data, and the performance of rival Alzheimer's Therapies.
- The bears won the battle - but will they win the war? I rate their chances >70/30.
For further details see:
Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate